Pharming Group (NASDAQ:PHAR) Trading Down 8.8%

Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price traded down 8.8% during trading on Friday . The stock traded as low as $9.53 and last traded at $9.53. 1,241 shares were traded during mid-day trading, a decline of 52% from the average session volume of 2,603 shares. The stock had previously closed at $10.45.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Thursday, March 14th.

Pharming Group Stock Down 6.2 %

The company has a 50-day moving average price of $10.86 and a 200 day moving average price of $11.43. The firm has a market capitalization of $657.68 million, a PE ratio of -68.07 and a beta of 0.16. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.06 and a quick ratio of 3.33.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, March 14th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.08). The firm had revenue of $81.20 million during the quarter, compared to analysts' expectations of $71.83 million. Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. Analysts forecast that Pharming Group will post -0.02 earnings per share for the current year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC bought a new position in Pharming Group (NASDAQ:PHAR - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,715 shares of the company's stock, valued at approximately $134,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.